NOVEL PHARMACEUTICALLY ACTIVE FLAVILIUM COMPOUNDS

Abstract: The present invention relates to novel flavilium derivatives of general formula (I) wherein X is a non-toxic anion, R1 and R2 are independently selected from hydrogen or -OY group in which Y is hydrogen, (alpha)-amino-acyl group or amino-alkyl group of 1 to 5 carbon atoms; R5 is hydrogen, (alpha)-amino-acyl group or amino-alkyl group of 1 to 5 carbon atoms; R3, R4, and R7 independently are hydrogen or alkyl group of 1 to 5 carbon atoms, R6 is hydrogen, hydroxy group or alkyl group of 1 to 5 carbon atoms. The compounds of general formula (I) possess outstanding selective anti-viral effect.

Description: NOVEL PHARMACEUTICALLY ACTIVE FLAVILIUM COMPOUNDS The present invention relates to novel flavilium derivatives of general formula (I) wherein X is a non-toxic anion, R-L and R 2 are independently selected from hydrogen or -OY group in which Y is hydrogen, α-amino-acyl group or amino-alkyl group of 1 to 5 carbon atoms; R 5 is hydrogen, α-amino-acyl group or amino-alkyl group of 1 to 5 carbon atoms; R3, R 4 , and R 7 independently are hydrogen or alkyl group of 1 to 5 carbon atoms, Rg is hydrogen, hydroxy group or alkyl group of 1 to 5 carbon atoms. In the general formula (I) Y, R3, R 4 , R5 Rg and R 7 can be an alkyl group of 1 to 5 carbon atoms e.g. methyl, ethyl, propyl, isopropyl, n-butyl, sec-butyl terc-butyl, n-pentyl or isopentyl group, preferably methyl group; the A-amino-acyl group can be the acyl radical of an essential amino acid, preferably glicyl, alanyl, lysyl or arginyl group. The compounds of general formula (I) possess outstanding selective anti-viral effect. Their effect against HIV virus is particularly important; comparing them to AZT they proved to be more effective and less toxic. The flavanoids are well-known wide-spread colour subs¬ tances in the flora. Flavilium salts form a type of this family of compounds. These salts are widely used in food industry e.g. for colouring fruits and other vegetable foods (e.g. German Patent No. 1,904,810, GDR Patent No. 140,353, US Patent No. 3,314,975). Medical application of flavilium derivatives, their lipid and colesterin level decreasing effect is described in European Patent No. 19,524, German Patent No. 2,808,820, while the effect of flavilium chloride similar to that of vitamin P is described in German Patents No. 2,002,421 and No. 2,703,375. Flavilium derivatives can be obtained from plant by various extraction methods or by synthetic procedures. According to one of synthetic methods a suitable phenol derivative is condensed with a substituted chalcone or phenyl-β-diketon e.g. pursuant to German Patent No. 1,904,810 and No. 2,808,823 or α-chloro-J3-N,N-dimethyl- formimidoyl-styrene perchlorate is used as a condensation partner in order to produce 7-amino-flavilium salts, in accordance with GDR Patent No. 140,353. According to the other possible way of reaction the desired compounds are prepared from a natural vegetable basic material by various reuσing methods (Mg + sulfuric acid, LiAlH^ Zn + acetic anhydride) (German Patents No. 2,002,421 and No. 2,703,375, European Patent No. 19,524 and Japanese Patent No. 55,036,679). According to our experience preparation of compounds of general formula (I) can not be realized by the above methods partly because there is no suitable vegetable basic material and because the methylated coumarin derivative and methylated phenol starting materials practically do not go into condensation reaction under normal conditions. It is well known that according to the Goswami- Chakravarti synthesis coumarin is condensed with resorcine in such a way that the reactants are heated in the presence of phosphorus oxychloride of catalytic amount (J. Ind. Che . Soc. 9_, 599, 1932). We found that the compounds of general formula (I) can be prepared by analogy to Goswami-Chakravarti synthesis in such a way that a phenol derivative of general formula (II) , wherein R4, and R7 are hydrogen or alkyl group of 1 to 5 carbon atoms; Rg is hydrogen R 6 is hydrogen, hydroxy or alkyl group of 1 to 5 carbon atoms is condensed with a coumarin derivative of general formula (III), wherein R^ and R 2 are hydrogen or hydroxy group; R3 is hydrogen or alkyl group of 1 to 5 carbon atoms. Condensation is performed in the presence of a much higher amount of phosphorus oxychloride than the amount used in the above-mentioned reactions. It is preferable to use 1.0 to 1.5 moles of phosphorus oxychloride calculated for the reactants. Instead of phosphorus oxychloride Lewis acids e.g. zinc chloride can also be used. Condensation takes place at a temperature in the range 70 to 115°C in the course of reaction. In order to obtain a better yield it is preferable to use hydrochloric acid gas. In that case the reaction takes place at room temperature, as well. Alternatively, compounds of general formula (I) can be obtained by condensing a phenole of the general formula (II), wherein R4, and R 7 are hydrogen or alkyl group of 1 to 5 carbon atoms; Rg is acetoacetyl group; Rg is hydrogen, hydroxy or alkyl group of 1 to 5 carbon atoms with a compound of general formula (IV), wherein R^ and R 2 are hydrogen or hydroxy group. Preferably the condensation is performed at a tempera- ture between 15 and 30°C in the presence of hydrochlric acid gas. In both of the above procedures the hydroσhloride salt is separated and in optional cases another pharmaceutically accepted salt is prepared by a ususal method. If desired, the compound of general formula (I) wherein Y and/or R^ are hydrogen is i/ transformed into an ester with an α-amino-acid, or ii/ reacted with an amino-alkyl-halide of 1 to 5 carbon atoms. Esterification can be carried out e.g. by coupling the suitable compound of formula (I) with an N-protected α-amino-acid by means of a coupling reagent such as dicyclohexilcarbodiimide. The amino protecting group can be a usual protecting group e.g. tertiary butoxy-carbonyl group is to be removed by acidic treatment after the coupling reaction. In order to examine the anti-HIV effect of compounds of general formula I the reverz transcriptase activity was measured ( Hoffman, A. D. et al. Virology 147, 326-335 1985) . Our results are demonstrated by means of the model compound 5,7,4'-trihydroxy-4,3' ,5'-trimethyl-flavilium chloride (BIOGAL 6) obtained according to Example 1. Cell and virus. To test the active agents we used MT-4 cell-line infected with strain HIV-1 IIIB. The cells were infected with 20 TCID 5Q HIV-1 virus. The testing procedure. The following concnetrations of the 3 active agents were tested of 5 μg/cm , 20 μg/cm and 100 μg/cm . The active agent was added to the culture first 4 hours before the infection, than 24 and 48 hours after infection. We used HIV infected, untreated MT-4 cells and uninfected, untreated cells as a control. Retrovir we used for the azidothimidin (AZT)-control was purchased from firm Wellcome. Study of the reverz transcriptase activity. We took 500 μl aliquots from supernatant of the culture and measured their virus concentration. The result are given in cpm/crrr which indicates 3 H-TTP. Results. Table 1 shows the activity level of revers transcriptase indicating the effect on virus production. The activity was measured every 3-4 days, but Table 1 shows only the represesentative results from the 7th, 10th, and 18th days. Table 1 Effect of the BIOGAL 6 and AZT on the HIV virus propagation As one can see BIOGAL-6 compound completely blocked the HIV production at 5 μg/c concentration. AZT also suppressed HIV proliferation at 5 μg/cm° concentration but this effect was shorter than the effect of BIOGAL-6 compound. Comparison of effects of BIOGAL-6 compound and AZT The effects of both compounds were tested at the following concentrations: 5.0, 2.5, 1.0, 0.5, 0.1 μg/cm 3 . Table 2 summarizes representative results. One csn see that BIOGAL- 6 compound was completely ineffective at 1.0 and less 1.0 μg/cm concentrations. However the effect of BIOGAL-6 compound at 5.0 and 2.5 μg/cm 3 concentrations was long- lasting, while administration of AZT had temporary effect even in higher concentrations. Table 2 Comparison of effects of BIOGAL-6 and AZT Fig. 1 shows the kinetics of the effect of BIOGAL-6 compound. As the Figure 1 shows BIOGAL-6 compound completely blocked HIV production at 5μg/cm 3 concentration, while AZT at the same concentration only delayed the HIV production but did not change the proliferation rate. The effect of BIOGAL-6 compound compared to AZT was long- lasting. This difference suggests that the two compounds exert their action through different mechanisms. According to the acut toxitity examinations (CFLP/SPF mice; per os and i. v.) the BIOGAL-6 compound is not toxic. The invention is illustrating in detail by aid of the following non-limiting Examples. Example 1 Preparation of 5,7,4'-trihydroxy-4,3' ,5'-trimethyl-flavi- lium chloride: 4-methyl-5,7-dihydroxy-coumarin (3.842 g) and 2,6-dimethyl- phenol (2,44 g) are kept boiling with total reflux in the presence of 10 cm 3 of P0C1 3 ans 3 g of ZnCl 2 at 100°C for 30 minutes then the mixture is poured into 200 cm 3 of icy • 3 water. The precipitate is dissolved in 100 cm of methanol. The methanol solution is treated with 3 dπr of ethyl acetate. The precipitate is filtered off, dissolved in methanil and chromatografed on Fractogel PGM 2000 adsorbent. The eluted material is recovered under reduced pressure at 60"C in a rotary waporater. The ethyl acetate separation and the chromatographic purification steps are repeated if necessary. Identification data of the product: R^: 0.58 Merck Cellulose (5632) water: hydrochloric acid: acetic acid = 3:2:5 v/v 1 H NMR (200 MH; DMSO d6 : 2.25 pp : 2 CH 3 ; 2.96 ppm: 1 CH 3 ; 6.8-6.925 ppm: H6, H8; 8.0 ppm: H2', H6'; 8,025 ppm: H3 Example 2 Preparation of 5,7,4'-trihydroxy-4,3' ,5'-trimethyl-flavi- lium chloride: 4 g of 2,6-dimethyl-4-acetoacetyl-phenol and 4 g of phloroglucinol are dissolved in 80 ml of water-free ethyl alcohol then hydrochloric acid gas is introduced and the solution is stirred at room temperature. Progress of the reaction is followed by thin layer chromatography. When the ring-closure is finished (appr. 8 ours) the reaction mixture is poured into water, the precipitate is filtered off and purified by column chromatography. Yield: 4,23 g Identification data of the product are the same as those described in Example 1. Example 3 Preparation of 4'5,7-trihydroxy-4,3' ,5'-trimethyl flavilium chloride-5,7-dialanyl ester 1.3 g pf the compound prepared according to Example 1 is reacted with 1.5 g of N-BOC-alanine (BOC = terc butoxy- carbonyl gruop) in the presence of .1.6 g of dicyclohexyl- carbodiimide. At the end of the reaction the precipitated diciclohexyl-urea is filtered off, the solvent is removed from the filtrate and the residue is dissolved in ethyl acetate. The solution is evaporated again and the title product is obtained after removing the protecting group by acidic treatment. Yield: 1.6 g

Claims: What we claim is 1. Compounds of the formula (I) wherein X is a non-toxic anion; R j^ and R 2 are independently selected from hydrogen or -OY group in which Y is hydrogen, α-amino-acyl group or amino-alkyl group of 1 to 5 carbonatoms; Rg is hydrogen, α-amino-acyl group or amino-alkyl group of 1 to 5 carbon atoms; R3, R4, and R 7 independently are hydrogen or alkyl group of 1 to 5 carbon atoms; R is hydrogen, hydroxy group or alkyl group of 1 to 5 carbon atoms. 2. A compound of the formula (I) as claimed in calim 1, wherein X is chloride ion; R j and R are -OY group in which Y is amino-alkyl group of 1 to 5 carbon atoms or glicyl, alanyl, lysyl or arginyl group; R5 hydrogen; R3, R4, and R hydrogen or methyl group; R fi is hydrogen, hydroxy group or methyl group. 3. 5 , 7 , 4 '-trihydrσxy-4 , 3 ' , 5 '-trimetil-f lavilium chloride . 4 . A pharmaceutical composition , which comprises an effective amount of a compound of the formula ( I ) , wherein X is a non-toxic anion; R j and R 2 are independently sleeted from hydrogen or -OY group in which Y is hydrogen, α-amino-acyl group or amino-alkyl group of 1 to 5 carbon atoms; R 5 is hydrogen, α-amino-acyl group or amino-alkyl group of 1 to 5 carbon atoms; R , R4, and R 7 independently are hydrogen or alkyl group of 1 to 5 carbon atoms; Rg is hydrogen, hydroxy group or alkyl group of 1 to 5 carbon atoms; together with a pharmaceutically acceptable diluent or carrier. 5. A composition as claimed in claim 4, which comprises an effective amount of a compound of the formula (I), wherein X is chloride ion; R j L and R 2 are -OY group in which Y is amino-alkyl group of 1 to 5 carbon atoms or gliσyl, alanyl, lysyl or arginyl group; R5 hydrogen; R3, R4, and R. hydrogen or methyl group; Rg is hydrogen, hydroxy group or methyl group; as active ingredient. 6. A composition as claimed in claim 4, which comprises 5,7,4'-trihydroxy-4,3',5'-trimetil-flavilium chloride as active ingredient. 7. A process for the preparation of compounds of the formula (I) I wherein X is a non-toxic anion; R^ and R 2 are independently selected from hydrogen or -OY group in which Y is hydrogen, α-amino-acyl group or amino-alkyl group of 1 to 5 carbon atoms or; R 5 is hydrogen, α-amino-acyl group or amino-alkyl group of 1 to 5 carbon atoms; R 3 , R 4 , and R 7 independently are hydrogen or alkyl group of 1 to 5 carbon atoms; Rg is hydrogen, hydroxy group or alkyl group of 1 to 5 carbon atoms. which is characterised in that: a) a phenol derivative of the formula (II) wherein R4, and R 7 are hydrogen or alkyl group of 1 to 5 carbon atoms; Rg is hydrogen, hydroxy or alkyl group of 1 to 5 carbon atoms; Rg is hydrogen is condensed with a coumarin derivative of the formula (III), wherein R^ and R 2 are hydrogen or hydroxy group; R3 is hydrogen or alkyl group of 1 to 5 carbon atoms; or b) a phenol derivative of formula (II) wherein R , and R 7 are hydrogen or alkyl group of 1 to 5 carbon atoms; Rg is hydrogen, hydroxy or alkyl group of 1 to 5 carbon atoms R is acetoacetyl group; is condensed with a compound of the formula (IV), wherein R^ and R 2 are hydrogen or hydroxy group; in the presence phosphorus oxychloride or hidroσhloric acid gas and if desired a compound of formula (I) wherein Y and/or R 5 are hydrogen is i) transformed into an ester with an α-amino-acid; or ii) reacted with an amino-alkyl-halide of 1 to 5 carbon atoms. 8. Use of the compounds of formula (I) I wherein X is a non-toxic anion; R^ and R 2 are independently selected from hydrogen or -OY group in which Y is hydrogen, α-amino-acyl group or amino-alkyl group of 1 to 5 carbon atoms; R 5 is hydrogen, α-amino-acyl group or amino-alkyl group of 1 to 5 carbon atoms; R , R4, and R 7 independently are hydrogen or alkyl group of 1 to 5 carbon atoms; Rg is hydrogen, hydroxy group or alkyl group of 1 to 5 carbon atoms; for the treatment of HIV virus infection. 9. Use of the compounds of formula (I) wherein X is chloride ion; R^ and R 2 are -OY group in which Y is amino-alkyl group of 1 to 5 carbon atoms or glicyl, alanyl, lysyl or arginyl grou; R t hydrogen; R3, R4, and R hydrogen or methyl group; Rg is hydrogen, hydroxy group or methyl group, for the treatment of HIV virus infection. 10. Use of 5,7,4'-trihydroxy-4,3',5'-trimetil-flavilium chloride for the treatment of HIV virus infection.

Inventors: BALINT JANOS, BORBELY ILDIKO, D TOTH FERENC, KISS JOLAN, SULYOK GYOERGY, BALINT, JANOS, BORBELY, ILDIKO, D. TOTH, FERENC, KISS, JOLAN, SULYOK, GYOERGY
Applicants: BALINT JANOS, BIOGAL GYOGYSZERGYAR, BORBELY ILDIKO, KISS JOLAN, SULYOK GYOERGY, TOTH FERENC D, BIOGAL GYOGYSZERGYAR RT.
Application year: 1993
Main classification: C07D311
IPC codes: A61K31, C07D311